According to QY Research Medical, the ulcerative colitis market was accounted at $6.2 billion in 2020 and it is expected to hit around $10.8 billion by 2030, registering growth at a CAGR of 5.9% from 2021 to 2030.
According to QY Research Medical, the ulcerative colitis market was accounted at $6.2 billion in 2020 and it is expected to hit around $10.8 billion by 2030, registering growth at a CAGR of 5.9% from 2021 to 2030.
Ulcerative colitis is a most common form of inflammatory bowel disease which affects several people. It causes inflammation and ulcers in digestive tract. Ulcerative colitis affects the innermost lining of large intestine and rectum. Ulcerative colitis develops at any age, but is commonly developed in people between the age of 15 and 30. The symptoms of ulcerative colitis vary from person to person and may include diarrhea, passing blood with your stool, and abdominal immune response.
Full Report is Ready | Request Sample of This Report @ https://qyresearchmedical.com/sample/112659
Growth of the global ulcerative colitis market is majorly driven by increase in prevalence of inflammatory gastrointestinal disorders, increase in the cases of ulcerative colitis, and development of drugs for treatment of ulcerative colitis by large number of key players. According to a survey conducted by Marc D Basson on Ulcerative Colitis in 2019, in the U.S., one million people were affected with ulcerative colitis. Prevalence of ulcerative colitis is the main reason for development of drugs to treat ulcerative colitis. Thus, with rise in burden of inflammatory bowel disease demand for ulcerative colitis increases, which, in turn, is anticipated to foster the growth of the ulcerative colitis market. Furthermore, according to a research study by Wing Yan Mak et al. published in Journal of Gastroenterology and Hepatology, in 2020, in Europe, North America, and Australia 23-34% of ulcerative colitis patients presented were with proctitis. In addition, in May 2021, Bristol Myers Squibb received approval from the U.S. Food and Drug Administration for the use of Zeposia for treating adults with moderately to severely active ulcerative colitis, a chronic inflammatory bowel disease. Therefore, rise in development of new drugs led to increase in the growth of the ulcerative colitis market opportunity.
Scope of the Report
| Report Coverage | Details |
| Market Size in 2020 | $6.2 Billion |
| Revenue Forecast by 2030 | $10.8 Billion |
| CAGR | 5.9% from 2021 to 2030 |
| Base Year | 2021 |
| Forecast Data | 2022 to 2030 |
Ulcerative colitis market segmentation
The ulcerative colitis market is segmented on the basis of route of administration, disease type, and molecule type. Depending on route of administration, it is categorized into oral and injectables.
According to disease type, it is classified into mild ulcerative colitis, moderate ulcerative colitis, and severe ulcerative colitis. By molecule type, it is divided into small molecules and biologics.
Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
Full Report is Ready | Quick Buy This Premium Report From Here: https://qyresearchmedical.com/report/checkout/112659/2900
Segment Review
Depending on route of administration, the oral segment dominated the ulcerative colitis market forecast, and this trend is expected to continue during the forecast period, owing to increase in R&D activities in the pharmaceutical & medical device industry, rise in demand for drugs required for treatment, and surge in adoption of various types of ulcerative colitis drugs. However, the injectables segment is expected to witness considerable growth during the forecast period, owing to increase in number of ulcerative colitis cases and growth in number of key players for development of new drugs in the medical device industry.
By disease type, the mild UC segment was the major contributor in 2020, and is expected to maintain its lead of ulcerative colitis market share during the forecast period, owing to increase in number of inflammatory bowel diseases, rise in the number of ulcerative colitis, and increase in demand for the treatment of ulcerative colitis. However, the moderate UC is expected to witness considerable ulcerative colitis market growth during the forecast period due to increase in number of ulcerative proctitis and rise in development of new ulcerative colitis drugs in the clinical laboratories. These are the factors which is bossting the ulcerative colitis market size.
On the basis of molecule type, the small molecule segment dominated the ulcerative colitis industry in 2020, and this trend is expected to continue during the forecast period, owing to large number key players offering drugs for treatment of ulcerative colitis and advancement in R&D activities. However, the biologics segment is expected to witness considerable growth during the forecast period, owing to increase in inflammatory gastrointestinal diseases and surge in usage of ulcerative colitis drugs.
Region wise, North America dominated the market in 2020, and is expected to be dominant during the forecast period, owing to rise in number of ulcerative colitis disease, presence of key players, development of the healthcare sector, and presence of new drugs in the region. However, Asia-Pacific is expected to register the highest CAGR of 6.5% from 2021 to 2030, owing to increase in prevalence of inflammatory bowel disease and development of healthcare infrastructure.
The key players that operate in the global ulcerative colitis market include Abbott Laboratories, Ajinomoto, Astrazeneca Plc., Eli-Lilly, GlaxoSmithKline Plc., Index Pharmaceuticals Holdings AB, Johnson & Johnson, Merck & Co., Pfizer Inc., and Sanofi.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the ulcerative colitis market analysis from 2020 to 2030 to identify the prevailing ulcerative colitis market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter’s five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the ulcerative colitis market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global ulcerative colitis market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
- By Disease Type
- Mild UC
- Moderate UC
- Severe UC
- By Molecule Type
- Biologics
- Small Molecules
- By Route of Administration
- Oral
- Injectables
- By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- North America
Key Market Players
- ABBOTT LABORATORIES
- AJINOMOTO CO. INC.
- ASTRAZENECA PLC
- ELI-LILLY
- INDEX PHARMACEUTICALS HOLDINGS AB
- GLAXOSIMITHKLINE PLC
- JOHNSON & JOHNSON
- Merck & Co. Inc.
- Pfizer Inc.
- SANOFI S.A
Full Report is Ready | Quick Buy This Premium Report From Here: https://qyresearchmedical.com/report/checkout/112659/2900
You can place an order or ask any questions, please feel free to contact sales@qyresearchmedical.com | +1 9197 992 333
About Us
QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team).
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world.
For Latest Update Follow Us:
https://www.linkedin.com/company/qyresearch-medical/
https://www.facebook.com/QYResearch-Medical-108186514228917/